Wegovy UK: a friendly guide to semaglutide for weight loss

Be clear about the medicine and the formulation

Wegovy acts on the GLP-1 receptor, helping regulate appetite. It is used alongside dietary changes and physical activity. The name now covers both an injection and a tablet, so ‘I take Wegovy’ is no longer enough information when asking about missed treatment, storage or switching.

Keep a photo of your dispensing label for appointments and have the pack nearby when contacting a pharmacist. Do not assume advice for Ozempic, Rybelsus or somebody else's Wegovy prescription applies to yours, even where the active ingredient is the same. Ask the clinician to write down the exact product and instructions.

Eligibility is a starting point for assessment

The adult weight-management licence covers an initial BMI of at least 30, or at least 27 with a weight-related health condition. A clinician also needs to assess your medical history, other treatments and whether the expected benefits justify the risks. This guide concerns adults; it is not a guide to treatment for children or teenagers.

Explain previous reactions to medicines, digestive problems, diabetes care and any eye conditions. Ask what will need monitoring if treatment starts. If you are planning pregnancy, semaglutide must be stopped at least two months before trying, with a clinician helping arrange appropriate care. Do not use someone else's eligibility decision as reassurance that the same treatment is right for you.

Read outcome claims with the study attached

Studies of semaglutide have shown weight-loss benefits when used with diet and activity support. The result depends on the formulation and treatment studied, who took part and how long they were followed. A figure from an injection study should not automatically be treated as the result for a tablet, or as your likely personal outcome.

Ask what a reasonable review plan would look like for you. You might agree to discuss weight, relevant health measurements, mobility and how well you are eating. Progress that is slower than a social-media example does not justify changing the prescription yourself. Equally, difficult side effects deserve attention even if weight is falling. The decision to continue should take both sides into account.

Decide what a worthwhile benefit would look like

It helps to agree your priorities before you start. You might want support with a weight-related health problem, improved mobility or a routine you can sustain around work and family. Discuss which changes the clinician will monitor, when you will meet again and how you will decide whether treatment remains worthwhile.

Weight loss varies between people. Publicity about the largest trial results is not a personal forecast. Tell your clinician if appetite changes leave you skipping most meals, feeling weak or struggling to drink. Ask for nutrition support if you are unsure how to eat enough of a balanced diet with a smaller appetite.

Keep a simple plan for questions and problems

Save the provider's clinical contact details somewhere easy to find. Check how quickly routine messages are answered and where to seek urgent help outside opening hours. Ask the team to explain the important warning signs in your leaflet rather than relying on a social-media list of ‘normal’ symptoms.

For semaglutide, sudden loss of vision or rapidly worsening eyesight needs urgent assessment at eye casualty or A&E. Severe, persistent abdominal pain also needs urgent medical attention. Discuss pregnancy plans before treatment; semaglutide should not be used during pregnancy. For everyday questions about your own prescription, the dispensing pharmacist is a practical first contact.

Work out access, cost and continuity together

NHS England describes injectable Wegovy access through specialist weight-management services. The relevant NICE weight-management recommendation includes a maximum two-year treatment period. Local criteria and arrangements must be checked, and these should not be assumed to apply automatically to Wegovy tablets.

For private care, ask for the usual ongoing cost, including consultations and delivery. Check what happens after an introductory offer and whether reviews are included. A low listed price is not evidence of clinical suitability. Before paying, identify who prescribes, who dispenses and who handles side effects. If you later want to change provider, ask how treatment records will be transferred and who will remain responsible while the handover is arranged.